Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
You can read the full article at Tirzepatide (TZP), a new dual GIP/GLP-1 receptor agonist for treating type 2 diabetes (T2D), displayed superior outcomes in HbA1c reduction and patients achieving target levels compared to semaglutide and titrated insulin degludec across 40-weeks (SURPASS-2) and 52-weeks (SURPASS-3) studies
Weight Loss One study found that after one year, participants with type 1 diabetes who took an SGLT-2 inhibitor had an average weight loss of 4.4 percent
10.2165/11590240-000000000-00000 63 FuchsH.BinderR.GreischelA
1 In total, 307 participants were randomized in a 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, alongside lifestyle intervention for 64 weeks
